Illumina Selected as a Preferred Service Provider for Cancer Research UK

Illumina, Inc. ILMN today announced that the company has been selected as a preferred service provider for Cancer Research UK. Illumina will provide a range of services, beginning with whole human genome sequencing, in support of the International Cancer Genome Consortium. The consortium is seeking to obtain a comprehensive description of genomic, transcriptomic and epigenomic changes in 50 different tumor types and/or subtypes of clinical and societal importance.